0 citations
OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinum-resistant ovarian cancer
Annals of Oncology2017Vol. 28, pp. v352–v352
Citations Over Time
Shibani Nicum, Victoria Y. Strauss, Naomi McGregor, Iain A. McNeish, René L. Roux, Marcia Hall, Agnieszka Michael, Corran Roberts
Related Papers
- → Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer(2016)157 cited
- → PARP inhibitors in ovarian cancer(2016)127 cited
- → Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer(2015)90 cited
- → Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts(2010)69 cited
- → Tolerance and Toxicity of the PARP Inhibitor Olaparib in Older Women with Ovarian Cancer(2017)1 cited